Comparative dosimetric evaluation of nanotargeted 188Re-(DXR)- liposome for internal radiotherapy

Cancer Biotherapy and Radiopharmaceuticals

Volumn 23, Issue 6, 2008, Pages 749-758

  Chang, Chih Hsien ^a   Stabin, Michael G ^b   Chang, Ya Jen ^a   Chen, Liang Cheng ^a   Chen, Min Hua ^c   Chang, Tsui Jung ^a   Lee, Te Wei ^a   Ting, Gann ^c,d  

^a INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

^b VANDERBILT UNIVERSITY   (United States)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Dosimetry; Doxorubicin; Internal radiotherapy; Pegylated nanoliposomes; Rhenium 188

Indexed keywords

DIAMINE; DOXORUBICIN RE 188; LIPO DOX; LIPOSOME; N,N BIS(2 MERCAPTOETHYL) N',N' DIETHYLETHYLENEDIAMINE RE 188; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES TUMOR; COLON CARCINOMA; CONTROLLED STUDY; DOSIMETRY; DRUG ABSORPTION; DRUG EXCRETION; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; SOLID TUMOR;

ANIMALS; ASCITES; COLONIC NEOPLASMS; DOXORUBICIN; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOTECHNOLOGY; POLYETHYLENE GLYCOLS; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RHENIUM; TISSUE DISTRIBUTION;

EID: 56249130692     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0489     Document Type: Article

References (27)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74.
2. Markman M. Intraperitoneal chemotherapy in the management of colon cancer. Semin Oncol 1999;26:536.
3. Allen TM, Cullis PR. Drug delivery systems: Entering the mainstream. Science 2004;303:1818.
4. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4:145.
5. Sadzuka Y, Hirota S, Sonobe T. Intraperitoneal administration of doxorubicin encapsulating liposomes against peritoneal dissemination. Toxicol Lett 2000;116:51.
6. Cabanes A, Tzemach D, Goren D, et al. Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model. Clin Cancer Res 1998;4:499.
7. Vaage J, Donovan D, Mayhew E, et al. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer 1993;72:3671.
8. Dancey JE, Chen HX. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 2006;5:649.
9. 188Re-BMEDA-liposome in a C26 murine colon carcinoma solid tumor animal model. Anticancer Res 2007;27:2217.
10. 188Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model. Nucl Med Biol 2007;34:415.
11. Milenic DE, Brady ED, Brechbiel MW. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 2004;3:488.
12. 186Re-SNS/S complexes: In vitro stability, imaging, and biodistribution in rats. J Nucl Med 2003;44:1992.
13. Sgouros G. Dosimetry of internal emitters. J Nucl Med 2005;46(Suppl 1):18S.
14. Measurements ICoRUa. Absorbed-dose specification in nuclear medicine. ICRU Report 67. J ICRU 2002;2:15
15. O'Donoghue JA, Baidoo N, Deland D, et al. Hematologic toxicity in radioimmunotherapy: Dose-response relationships for I-131-labeled antibody therapy. Cancer Biother Radiopharm 2002;17:435.
16. Emfietzoglou D, Kostarelos K, Sgouros G. An analytic dosimetry study for the use of radionuclide-liposome conjugates in internal radiotherapy. J Nucl Med 2001;42:499.
17. Emfietzoglou D, Kostarelos K, Papakostas A, et al. Liposome-mediated radiotherapeutics within avascular tumor spheroids: Comparative dosimetry study for various radionuclides, liposome systems, and a targeting antibody. J Nucl Med 2005;46:89.
18. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023.
19. Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys 2003;85:294.
20. 188Re-lanreotide in athymic mice with induced human cancer tumors. Int J Pharm 2006;310:125.
21. Bentel GC, Nelson CE, Noell KT. Treatment Planning and Dose Calculation in Radiation Oncology, 4th ed Elmsford, NY: Oergamon Press, 1989.
22. Kostarelos K, Emfietzoglou D. Tissue dosimetry of liposome-radionuclide complexes for internal radiotherapy: Toward liposome-targeted therapeutic radiopharmaceuticals. Anticancer Res 2000;20:3339.
23. Cremonesi M, Ferrari M, Bodei L, et al. Dosimetry in peptide radionuclide receptor therapy: A review. J Nucl Med 2006;47:1467.
24. 111In-DTPA- human epidermal growth factor: An auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer. J Nucl Med 2006;47:1023.
25. 111ln-DTPA-labelled pegylated liposomes in a human tumour xenograft model. Br J Cancer 2000;83:684.
26. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996;14:1974.
27. Wahl RL. The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I-131 tositumomab. Semin Oncol 2003;30:31.